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(89%). Predictors of second treatment after biochemical
failure for RP included PSA at diagnosis (p < .0001), T
stage (p = .0062) and biopsy Gleason score (p = .0109).
Patients with a PSA > 20, T3 disease and Gleason 8–10
had a 4.5 fold, 3.6 fold and 3.5 fold increased risk of
second treatment as compared to patients with a PSA <
4, T1 disease, and Gleason 2–6, respectively. For XRT,
predictors of second treatment included biopsy Gleason
score (p < .0001) and PSA at diagnosis (p = .0057).
Patients with Gleason 8–10 and PSA > 20 had a 5.4 fold
and 6.5 fold increased risk of second treatment as com-
pared to patients with Gleason 2–6 and PSA < 4, respec-
tively. CONCLUSION: Second treatment timing and type
differs for RP and XRT patients who fail biochemically.
Pretreatment clinical factors can be used to determine
which patients are at highest risk for second treatment.
This has implications for initial treatment efﬁcacy.
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DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS
(Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY
WEEK (QW) IN CHEMOTHERAPY-INDUCED
ANEMIA PATIENTS RESULT IN SIMILAR INITIAL
HEMOGLOBIN OUTCOMES
Patton J1, Wallace JF2
1Tennessee Oncology Southern Hills, Nashville,TN, USA;
2Amgen Inc,Thousand Oaks, CA, USA
Darbepoetin alfa (Aranesp®, DA), a unique erythropoi-
etic molecule with 3-fold longer half-life than epoetin alfa
(EPO), is indicated for treatment of chemotherapy-
induced anemia (CIA). OBJECTIVE: To determine the
most common initial dosing regimens for DA and EPO in
clinical practice and evaluate their effectiveness after four
weeks of therapy. METHODS: In order to determine
which initial regimens are most commonly used in prac-
tice as well as their effectiveness, we conducted a chart
review within Tennessee Oncology. Tennessee Oncology,
a major provider of cancer care in the Nashville area, 
has collected extensive data on EPO and DA use as part
of their quality assurance process. DA patients switched
from EPO were not eligible for the analysis. Mean hemo-
globin changes were not adjusted for transfusions.
RESULTS: Of 408 patients treated with an erythropoetic
agent, 196 received DA and 212 received EPO. The
majority of EPO patients (86.3%) had an initial dosing
schedule of 40,000 U QW (EPO40KQW). The majority
of DA patients received a ﬁxed dose. Of 196 DA patients,
97 (49.5%) received 100 mcg QW (DA100QW) and 70
(35.7%) received 200 mcg Q2W (DA200Q2W). Hemo-
globin (hgb) values were collected at baseline and begin-
ning of week 5. Mean baseline hgb (g/dL) [95% CL] for
the DA100QW, DA200Q2W and EPO40KQW groups
were 10.2 [±0.15], 9.9 [±0.18], and 9.7 [±0.14], respec-
tively. Mean changes in hgb (g/dL) [95%CL] after 4
weeks of therapy for the DA100QW, DA200Q2W, and
EPO40KQW group were 0.9 [±0.24], 1.1 [±0.29], and
0.8 [±0.22], respectively. The median for each group was
very similar to the corresponding mean. CONCLU-
SIONS: These results establish that 200mcg Q2W DA
maintained dose efﬁciency when compared to 100mcg
QW and was at least as effective as 40,000 U QW of EPO
after 4 weeks therapy in patients with CIA.
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SURGICAL OUTCOME
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OBJECTIVES: In the era of restricted ﬁnancial resources
for health care different strategies are developed to 
optimize patient outcome, but all of them need a valid
outcome measurement. One of such concepts for surgical
patients is the McPeek-Score which was evaluated in three
trials. METHODS: The discontinuous McPeek-Score
gives 1 point for a patient who died in the operation
theatre, 2 for one who died in hospital postoperatively, 4
or 5 for a patient discharged alive with great or moder-
ate amount of ICU care, 7, 8 or 9 points for a routine
recovery with long, average or short postoperative 
hospitalization, respectively. The postoperative recovery
index of McPeek was used in 699 patients in 3 trials.
Patients in trial 1 had elective, colorectal cancer surgery,
in trial 2 oncological, endocrine, and vascular surgery,
and in trial 3 cholecystectomy. Reliability, validity, sensi-
tivity and practicability of the McPeek-Score were inves-
tigated. RESULTS: The score is reliable, because the
results were reproduced in three different hospitals and
by different investigators in one trial. Score points were
distributed over all classes with a maximum of 7–9
points. Validity of the score was demonstrated by corre-
lation to complication rate, ASA-Score, and age with 
correlation coefﬁcients of 0.6–0.7 in the 3 trials: The
score measures what it claims to measure. Sensitivity of
the McPeek-Score was shown in trial 2 by differences
between tumour- and non-tumour patients (8 vs. 7 points,
p < 0.001, chi-square-test) and in trial 3 between emer-
gency- and non-emergency patients (9 vs. 7 points, p <
0.001). The score is very practicable, because the surgeon
needs only a few minutes to get the score value, it does
not interfere with his routine tasks. CONCLUSIONS:
The McPeek-Score is well suited to assess outcome of sur-
gical procedures. It is only applicable to major surgical
situations where mortality and ICU treatment is of 
importance.
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OBJECTIVES: The cross-sectional life-years lost (LYL)
index is commonly used to estimate years of life losses at
a speciﬁc point in time. However, the deaths included 
in such index have already occurred and are no longer
preventable. We sought to develop and use a potentially
more valuable measure, the expected remaining lifetime
years of potential life lost (i.e., LYPLL), for 21 major
cancers. METHODS: To estimate LPYLL, we used life
table techniques, U.S. population data from the U.S.
Bureau of the Census, and Surveillance, Epidemiology,
and End Results (SEER) data on the cancer-speciﬁc, age-
speciﬁc incidence and relative survival rates. We then
compared the resultant ﬁndings with published cross-
sectional LYL from SEER. RESULTS: The total number
of LYPLL per cancer ranged from 128,000 years
(Hodgkin’s lymphoma) to 2,055,000 years (lung/
bronchus cancer). The three leading causes of LYPLL
were lung/bronchus, female breast, colon/rectum, and
prostate cancer. In comparison, lung/bronchus, colon/
rectum, female breast, and pancreatic cancer were the
three leading causes of cross-sectional LYL. The average
LYPLL per cancer case ranged from 3.8 (prostate cancer)
to 16.8 years (Hodgkin’s lymphoma). Hodgkin’s lym-
phoma, brain and cervix cancer had the highest LYPLL
per case (16.8, 16.5, and 15.7 LYPLL per case, respec-
tively). The undiscounted LYPLL calculation results in a
similar rank in all cancers, with LYPLL of 3,144, 2,814,
and 1,993 thousand years for female breast, lung/
bronchus, colon/rectum, and prostate cancer, respectively.
CONCLUSIONS: The longitudinal LYPLL measure may
be more relevant than cross-sectional LYL index when
setting preventive intervention priority and goals. A
natural extension of the LYLLP method could be used to
better understand the economic burden of cancer and the
potential quality-adjusted life years lost. Ultimately, this
information could be used to determine more deﬁnitively
the cost-effectiveness of cancer prevention strategies (e.g.,
smoking cessation programs and cancer screening tech-
nologies and policies).
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HEALTHCARE EXPENDITURES ASSOCIATED
WITH SEVEN TUMOR TYPES OF INTEREST
(TOI) USING LARGE EMPLOYERS’ CLAIMS
DATABASE
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OBJECTIVES: To evaluate healthcare expenditures asso-
ciated with treatment of seven TOI and deﬁne a burden
of TOI to the healthcare. METHODS: Retrospective
case-control study was conducted using MarketScanTM
claims databases of over 3 million US employees, spouses,
dependents, and early retirees. Cases were newly diag-
nosed with TOI in 1999–2000 (index date). Cases had no
cancer diagnosis for 12 months prior to index date and
had conﬁrming diagnosis of TOI within 3 months of the
index date. Control groups were members without cancer
diagnosis and matched 3:1 with each case group (97.5%
match) on gender, age, health coverage, region, and
follow-up period. Monthly healthcare expenditures were
estimated, adjusting for age, gender, Charlson Comor-
bidity Index, region, follow-up period, and hospital 
mortality using ordinary least squares with logarithmic
transformation. Due to left-skewed distribution, regres-
sion-adjusted expenditures of controls were estimated
using two-part models. Re-transformed expenditures
(using smearing estimator) were compared with a t-test.
RESULTS: The study consisted of 12,709 cases and
38,127 controls. Cases included 43% prostate, 22% 
colorectal, 16% lung, 5% brain, 3% ovarian and 3%
pancreatic cancer, and 8% Non-Hodgkin’s lymphoma
patients. Mean follow-up period was 11 months. Mean
monthly healthcare expenditures for cases were $3905
(SD = $2647) vs. $329 (SD = $446) for controls (p <
0.0001). The highest expenditures were associated with
pancreatic ($7613 vs. controls $334), ovarian ($6373 vs.
controls $281), brain ($6364 vs. controls $277), and lung
($6520 vs. controls $339) cancer. Except in prostate
cancer, inpatient services drove the expenditures in all
TOI. CONCLUSIONS: Mean monthly healthcare expen-
ditures associated with TOI were almost 12 times higher
compared to controls. Pancreatic, ovarian and brain
cancer patients had 20 times higher expenditures than
control groups. The burden of the seven tumors to the
healthcare system is substantial and suggests a need for
increased prevention or new therapies to reduce resource
use and healthcare expenditures.
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DOSE CONVERSION OF ERYTHROPOIETIC
AGENTS IN CHEMOTHERAPY-INDUCED
ANEMIA:A META-ANALYSIS
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OBJECTIVES: For purposes of a payment policy, the
Centers for Medicare and Medicaid Services (CMS) have
adopted a dose conversion ratio (DCR) of 260 U epoetin
alfa (EPO) to 1 mcg darbepoetin alfa (DARB). A meta-
analysis was conducted based on all available clinical trial
information to estimate a DCR at which the two drugs
were equally effective in increasing hemoglobin levels in
patients with chemotherapy-induced anemia (CIA), mea-
sured by the area under the curve (AUC) of hemoglobin
change at weeks 4 and 13. METHODS: A search of
PUBMED, CANCERLIT and references for papers and
abstracts reporting on clinical trials of DARB or EPO in
treating CIA resulted in the identiﬁcation of 49 publica-
tions. Eleven papers met prospective criteria for eligibil-
ity in the meta-analysis, which included employing a
prospective study design and reporting baseline hemo-
globin concentration, change in hemoglobin concentra-
tion, tumor type and either mean dose of study drug or
proportion of patients requiring dose escalation. The
DCR is based on the ratio of the coefﬁcients on DARB
